



Highly Selective SARM-Like Compounds for The Treatment of Age Related Sarcopenia: Part 2

The Continuation of Part 1 of Related Article Regarding the Usage of SARM-Like Compounds for The Treatment of Geriatric Cachexia and Other Senility Related Sarcopenic Conditions.



HEALTH

PART 2

In order to achieve the aforesaid advantages, the invention is a composition for preventing geriatric cachexia, said composition being obtained by the components selected from the group comprising alpha-methyldioscin, tinaspora cordifolia, 20-(s)-b-ginsenoside rh2 that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and, therefore, the evaluation must be made taking this detailed description into consideration.

Detailed Description of the Invention

The invention is a composition formed for the prevention of geriatric cachexia. Alpha-methyldioscin, which is a rare derivative of dioscin, a furastanol saponin derivative naturally contained by the family dioscorea, both stimulates the release of the natural growth hormone and exhibits neurotrophic action on the neuromuscular junction. Thus, it promotes the increase of the number of the muscle cells, the repair of the connective tissue and the increase of the muscle strength. It strengthens the cardiac muscle and increases the ability of contraction. It provides the blood pressure-reducing and blood sugar-reducing effect by increasing the expression of nitric oxide

synthase.

Tinaspora cordifolia extract (10:1), another ingredient of the invention, has partial androgenic activity. This extract binds to the androgen receptors to exhibit both myotropic (muscle mass-increasing) and contraction force-increasing action like testosterone and DHT. It exhibits the ability to treat the receptor reduction caused by synthetic testosterone derivatives. It provides support for the activities that require long time effort, by stabilizing the blood sugar.

20-(S)-B-Ginsenoside, rh2, another ingredient of the invention, owing to its ability to stimulate the AMPA receptor, increases the nervous system efficiency and provides active increase in the reflexes. It accelerates the bone healing by increasing the alkaline phosphatase expression following the bone fractures. It increases the osteoblast production and balances the blood sugar. Owing to its bronchodilating property and its ability to stimulate the AMPA receptor, it increases the breathing capacity. It improves the contraction ability owing to the pro-cholinergic action on the neuromuscular junction. It prevents the excessive thinning or thickening of the blood owing to the coagulation-regulating action, thereby preventing the circulatory disorders likely to result both from internal bleeding and embolisms.

The composition according to the invention contains alpha-methyldioscin, tinaspora cordifolia, 20-(s)-Ginsenoside RH2

Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:

20-50% alpha-methyldioscin,
75-40% Tinaspora Cordifolia extract (10:1),
5-10% 20-(s)-B-ginsenoside rh2.

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for preventing geriatric cachexia and the manufacture thereof for this purpose.

CLAIMS

1. A composition for preventing geriatric cachexia, said composition being obtained by the components selected from the group comprising alpha-methyldioscin, tinaspora cordifolia extract, 20-(s)-bginsenoside rh2 that are used individually or in combinations.


2. A composition according to Claim 1 characterized in that it comprises 20-50% by weight alphamethyldioscin.

3. A composition according to Claim 1 characterized in that it comprises 75-40% by weight tinasporea cordifolia extract (10:1).
4. A composition according to Claim 1 characterized in that it comprises 5-10% by weight 20-(s)-Bginsenoside rh2.

Above Mentioned Compounds and Techniques may provide an effective and sustainable cure for age related Sarcopenia.

Contributor

Contributed by

MAS Pharmaceuticals
34140 ISTANBUL
Türkiye 

Last update: 30 September 2020

Permalink: <https://cordis.europa.eu/article/id/413270-highly-selective-sarm-like-compounds-for-the-treatment-of-age-related-sarcopenia-part-2>

European Union, 2025